カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の組換えDNAワクチン市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Recombinant DNA Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19597）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19597
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：90
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の組換えDNAワクチン市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

組換えDNAワクチン市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の組換えDNAワクチンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

組換えDNAワクチン市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・組換えタンパク質ワクチン、遺伝子ベースワクチン

用途別セグメントは次のように区分されます。
・人間、動物

世界の組換えDNAワクチン市場の主要な市場プレーヤーは以下のとおりです。
・Merck、GSK、Sanofi、Zoties、Elanco、Boehringer-Ingelheim、Indian Immunologicals、Plumbline Life Sciences

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、組換えDNAワクチン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な組換えDNAワクチンメーカーの企業概要、2019年～2022年までの組換えDNAワクチンの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な組換えDNAワクチンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別組換えDNAワクチンの販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの組換えDNAワクチンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での組換えDNAワクチン市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および組換えDNAワクチンの産業チェーンを掲載しています。
・第13、14、15章では、組換えDNAワクチンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 組換えDNAワクチンの概要
- 種類別分析（2017年vs2021年vs2028年）：組換えタンパク質ワクチン、遺伝子ベースワクチン
- 用途別分析（2017年vs2021年vs2028年）：人間、動物
- 世界の組換えDNAワクチン市場規模・予測
- 世界の組換えDNAワクチン生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Merck、GSK、Sanofi、Zoties、Elanco、Boehringer-Ingelheim、Indian Immunologicals、Plumbline Life Sciences
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：組換えタンパク質ワクチン、遺伝子ベースワクチン
・用途別分析2017年-2028年：人間、動物
・組換えDNAワクチンの北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・組換えDNAワクチンのヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・組換えDNAワクチンのアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・組換えDNAワクチンの南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・組換えDNAワクチンの中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Recombinant DNA Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Recombinant DNA Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Human accounting for % of the Recombinant DNA Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Recombinant Protein Vaccine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Recombinant DNA Vaccine include Merck, GSK, Sanofi, Zoties, and Elanco, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Recombinant DNA Vaccine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Recombinant Protein Vaccine
Gene-Based Vaccine
Market segment by Application can be divided into
Human
Animal
The key market players for global Recombinant DNA Vaccine market are listed below:
Merck
GSK
Sanofi
Zoties
Elanco
Boehringer-Ingelheim
Indian Immunologicals
Plumbline Life Sciences
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant DNA Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Recombinant DNA Vaccine, with price, sales, revenue and global market share of Recombinant DNA Vaccine from 2019 to 2022.
Chapter 3, the Recombinant DNA Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant DNA Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Recombinant DNA Vaccine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant DNA Vaccine.
Chapter 13, 14, and 15, to describe Recombinant DNA Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Recombinant DNA Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Recombinant DNA Vaccine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Recombinant Protein Vaccine
1.2.3 Gene-Based Vaccine
1.3 Market Analysis by Application
1.3.1 Overview: Global Recombinant DNA Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Human
1.3.3 Animal
1.4 Global Recombinant DNA Vaccine Market Size & Forecast
1.4.1 Global Recombinant DNA Vaccine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Recombinant DNA Vaccine Sales in Volume (2017-2028)
1.4.3 Global Recombinant DNA Vaccine Price (2017-2028)
1.5 Global Recombinant DNA Vaccine Production Capacity Analysis
1.5.1 Global Recombinant DNA Vaccine Total Production Capacity (2017-2028)
1.5.2 Global Recombinant DNA Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Recombinant DNA Vaccine Market Drivers
1.6.2 Recombinant DNA Vaccine Market Restraints
1.6.3 Recombinant DNA Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Recombinant DNA Vaccine Product and Services
2.1.4 Merck Recombinant DNA Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK Recombinant DNA Vaccine Product and Services
2.2.4 GSK Recombinant DNA Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi Recombinant DNA Vaccine Product and Services
2.3.4 Sanofi Recombinant DNA Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Zoties
2.4.1 Zoties Details
2.4.2 Zoties Major Business
2.4.3 Zoties Recombinant DNA Vaccine Product and Services
2.4.4 Zoties Recombinant DNA Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Elanco
2.5.1 Elanco Details
2.5.2 Elanco Major Business
2.5.3 Elanco Recombinant DNA Vaccine Product and Services
2.5.4 Elanco Recombinant DNA Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Boehringer-Ingelheim
2.6.1 Boehringer-Ingelheim Details
2.6.2 Boehringer-Ingelheim Major Business
2.6.3 Boehringer-Ingelheim Recombinant DNA Vaccine Product and Services
2.6.4 Boehringer-Ingelheim Recombinant DNA Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Indian Immunologicals
2.7.1 Indian Immunologicals Details
2.7.2 Indian Immunologicals Major Business
2.7.3 Indian Immunologicals Recombinant DNA Vaccine Product and Services
2.7.4 Indian Immunologicals Recombinant DNA Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Plumbline Life Sciences
2.8.1 Plumbline Life Sciences Details
2.8.2 Plumbline Life Sciences Major Business
2.8.3 Plumbline Life Sciences Recombinant DNA Vaccine Product and Services
2.8.4 Plumbline Life Sciences Recombinant DNA Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Recombinant DNA Vaccine Breakdown Data by Manufacturer
3.1 Global Recombinant DNA Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Recombinant DNA Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Recombinant DNA Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Recombinant DNA Vaccine Manufacturer Market Share in 2021
3.4.2 Top 6 Recombinant DNA Vaccine Manufacturer Market Share in 2021
3.5 Global Recombinant DNA Vaccine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Recombinant DNA Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Recombinant DNA Vaccine Market Size by Region
4.1.1 Global Recombinant DNA Vaccine Sales in Volume by Region (2017-2028)
4.1.2 Global Recombinant DNA Vaccine Revenue by Region (2017-2028)
4.2 North America Recombinant DNA Vaccine Revenue (2017-2028)
4.3 Europe Recombinant DNA Vaccine Revenue (2017-2028)
4.4 Asia-Pacific Recombinant DNA Vaccine Revenue (2017-2028)
4.5 South America Recombinant DNA Vaccine Revenue (2017-2028)
4.6 Middle East and Africa Recombinant DNA Vaccine Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Recombinant DNA Vaccine Sales in Volume by Type (2017-2028)
5.2 Global Recombinant DNA Vaccine Revenue by Type (2017-2028)
5.3 Global Recombinant DNA Vaccine Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Recombinant DNA Vaccine Sales in Volume by Application (2017-2028)
6.2 Global Recombinant DNA Vaccine Revenue by Application (2017-2028)
6.3 Global Recombinant DNA Vaccine Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Recombinant DNA Vaccine Sales by Type (2017-2028)
7.2 North America Recombinant DNA Vaccine Sales by Application (2017-2028)
7.3 North America Recombinant DNA Vaccine Market Size by Country
7.3.1 North America Recombinant DNA Vaccine Sales in Volume by Country (2017-2028)
7.3.2 North America Recombinant DNA Vaccine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Recombinant DNA Vaccine Sales by Type (2017-2028)
8.2 Europe Recombinant DNA Vaccine Sales by Application (2017-2028)
8.3 Europe Recombinant DNA Vaccine Market Size by Country
8.3.1 Europe Recombinant DNA Vaccine Sales in Volume by Country (2017-2028)
8.3.2 Europe Recombinant DNA Vaccine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Recombinant DNA Vaccine Sales by Type (2017-2028)
9.2 Asia-Pacific Recombinant DNA Vaccine Sales by Application (2017-2028)
9.3 Asia-Pacific Recombinant DNA Vaccine Market Size by Region
9.3.1 Asia-Pacific Recombinant DNA Vaccine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Recombinant DNA Vaccine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Recombinant DNA Vaccine Sales by Type (2017-2028)
10.2 South America Recombinant DNA Vaccine Sales by Application (2017-2028)
10.3 South America Recombinant DNA Vaccine Market Size by Country
10.3.1 South America Recombinant DNA Vaccine Sales in Volume by Country (2017-2028)
10.3.2 South America Recombinant DNA Vaccine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Recombinant DNA Vaccine Sales by Type (2017-2028)
11.2 Middle East & Africa Recombinant DNA Vaccine Sales by Application (2017-2028)
11.3 Middle East & Africa Recombinant DNA Vaccine Market Size by Country
11.3.1 Middle East & Africa Recombinant DNA Vaccine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Recombinant DNA Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Recombinant DNA Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Recombinant DNA Vaccine
12.3 Recombinant DNA Vaccine Production Process
12.4 Recombinant DNA Vaccine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Recombinant DNA Vaccine Typical Distributors
13.3 Recombinant DNA Vaccine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Recombinant DNA Vaccine Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Recombinant DNA Vaccine Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Merck Basic Information, Manufacturing Base and Competitors
Table 4. Merck Major Business
Table 5. Merck Recombinant DNA Vaccine Product and Services
Table 6. Merck Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. GSK Basic Information, Manufacturing Base and Competitors
Table 8. GSK Major Business
Table 9. GSK Recombinant DNA Vaccine Product and Services
Table 10. GSK Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Sanofi Basic Information, Manufacturing Base and Competitors
Table 12. Sanofi Major Business
Table 13. Sanofi Recombinant DNA Vaccine Product and Services
Table 14. Sanofi Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Zoties Basic Information, Manufacturing Base and Competitors
Table 16. Zoties Major Business
Table 17. Zoties Recombinant DNA Vaccine Product and Services
Table 18. Zoties Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Elanco Basic Information, Manufacturing Base and Competitors
Table 20. Elanco Major Business
Table 21. Elanco Recombinant DNA Vaccine Product and Services
Table 22. Elanco Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Boehringer-Ingelheim Basic Information, Manufacturing Base and Competitors
Table 24. Boehringer-Ingelheim Major Business
Table 25. Boehringer-Ingelheim Recombinant DNA Vaccine Product and Services
Table 26. Boehringer-Ingelheim Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Indian Immunologicals Basic Information, Manufacturing Base and Competitors
Table 28. Indian Immunologicals Major Business
Table 29. Indian Immunologicals Recombinant DNA Vaccine Product and Services
Table 30. Indian Immunologicals Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Plumbline Life Sciences Basic Information, Manufacturing Base and Competitors
Table 32. Plumbline Life Sciences Major Business
Table 33. Plumbline Life Sciences Recombinant DNA Vaccine Product and Services
Table 34. Plumbline Life Sciences Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Global Recombinant DNA Vaccine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 36. Global Recombinant DNA Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 37. Market Position of Manufacturers in Recombinant DNA Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 38. Global Recombinant DNA Vaccine Production Capacity by Company, (K Units): 2020 VS 2021
Table 39. Head Office and Recombinant DNA Vaccine Production Site of Key Manufacturer
Table 40. Recombinant DNA Vaccine New Entrant and Capacity Expansion Plans
Table 41. Recombinant DNA Vaccine Mergers & Acquisitions in the Past Five Years
Table 42. Global Recombinant DNA Vaccine Sales by Region (2017-2022) & (K Units)
Table 43. Global Recombinant DNA Vaccine Sales by Region (2023-2028) & (K Units)
Table 44. Global Recombinant DNA Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 45. Global Recombinant DNA Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 46. Global Recombinant DNA Vaccine Sales by Type (2017-2022) & (K Units)
Table 47. Global Recombinant DNA Vaccine Sales by Type (2023-2028) & (K Units)
Table 48. Global Recombinant DNA Vaccine Revenue by Type (2017-2022) & (USD Million)
Table 49. Global Recombinant DNA Vaccine Revenue by Type (2023-2028) & (USD Million)
Table 50. Global Recombinant DNA Vaccine Price by Type (2017-2022) & (US$/Unit)
Table 51. Global Recombinant DNA Vaccine Price by Type (2023-2028) & (US$/Unit)
Table 52. Global Recombinant DNA Vaccine Sales by Application (2017-2022) & (K Units)
Table 53. Global Recombinant DNA Vaccine Sales by Application (2023-2028) & (K Units)
Table 54. Global Recombinant DNA Vaccine Revenue by Application (2017-2022) & (USD Million)
Table 55. Global Recombinant DNA Vaccine Revenue by Application (2023-2028) & (USD Million)
Table 56. Global Recombinant DNA Vaccine Price by Application (2017-2022) & (US$/Unit)
Table 57. Global Recombinant DNA Vaccine Price by Application (2023-2028) & (US$/Unit)
Table 58. North America Recombinant DNA Vaccine Sales by Country (2017-2022) & (K Units)
Table 59. North America Recombinant DNA Vaccine Sales by Country (2023-2028) & (K Units)
Table 60. North America Recombinant DNA Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 61. North America Recombinant DNA Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 62. North America Recombinant DNA Vaccine Sales by Type (2017-2022) & (K Units)
Table 63. North America Recombinant DNA Vaccine Sales by Type (2023-2028) & (K Units)
Table 64. North America Recombinant DNA Vaccine Sales by Application (2017-2022) & (K Units)
Table 65. North America Recombinant DNA Vaccine Sales by Application (2023-2028) & (K Units)
Table 66. Europe Recombinant DNA Vaccine Sales by Country (2017-2022) & (K Units)
Table 67. Europe Recombinant DNA Vaccine Sales by Country (2023-2028) & (K Units)
Table 68. Europe Recombinant DNA Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 69. Europe Recombinant DNA Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 70. Europe Recombinant DNA Vaccine Sales by Type (2017-2022) & (K Units)
Table 71. Europe Recombinant DNA Vaccine Sales by Type (2023-2028) & (K Units)
Table 72. Europe Recombinant DNA Vaccine Sales by Application (2017-2022) & (K Units)
Table 73. Europe Recombinant DNA Vaccine Sales by Application (2023-2028) & (K Units)
Table 74. Asia-Pacific Recombinant DNA Vaccine Sales by Region (2017-2022) & (K Units)
Table 75. Asia-Pacific Recombinant DNA Vaccine Sales by Region (2023-2028) & (K Units)
Table 76. Asia-Pacific Recombinant DNA Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 77. Asia-Pacific Recombinant DNA Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 78. Asia-Pacific Recombinant DNA Vaccine Sales by Type (2017-2022) & (K Units)
Table 79. Asia-Pacific Recombinant DNA Vaccine Sales by Type (2023-2028) & (K Units)
Table 80. Asia-Pacific Recombinant DNA Vaccine Sales by Application (2017-2022) & (K Units)
Table 81. Asia-Pacific Recombinant DNA Vaccine Sales by Application (2023-2028) & (K Units)
Table 82. South America Recombinant DNA Vaccine Sales by Country (2017-2022) & (K Units)
Table 83. South America Recombinant DNA Vaccine Sales by Country (2023-2028) & (K Units)
Table 84. South America Recombinant DNA Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 85. South America Recombinant DNA Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 86. South America Recombinant DNA Vaccine Sales by Type (2017-2022) & (K Units)
Table 87. South America Recombinant DNA Vaccine Sales by Type (2023-2028) & (K Units)
Table 88. South America Recombinant DNA Vaccine Sales by Application (2017-2022) & (K Units)
Table 89. South America Recombinant DNA Vaccine Sales by Application (2023-2028) & (K Units)
Table 90. Middle East & Africa Recombinant DNA Vaccine Sales by Region (2017-2022) & (K Units)
Table 91. Middle East & Africa Recombinant DNA Vaccine Sales by Region (2023-2028) & (K Units)
Table 92. Middle East & Africa Recombinant DNA Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 93. Middle East & Africa Recombinant DNA Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 94. Middle East & Africa Recombinant DNA Vaccine Sales by Type (2017-2022) & (K Units)
Table 95. Middle East & Africa Recombinant DNA Vaccine Sales by Type (2023-2028) & (K Units)
Table 96. Middle East & Africa Recombinant DNA Vaccine Sales by Application (2017-2022) & (K Units)
Table 97. Middle East & Africa Recombinant DNA Vaccine Sales by Application (2023-2028) & (K Units)
Table 98. Recombinant DNA Vaccine Raw Material
Table 99. Key Manufacturers of Recombinant DNA Vaccine Raw Materials
Table 100. Direct Channel Pros & Cons
Table 101. Indirect Channel Pros & Cons
Table 102. Recombinant DNA Vaccine Typical Distributors
Table 103. Recombinant DNA Vaccine Typical Customers
List of Figures
Figure 1. Recombinant DNA Vaccine Picture
Figure 2. Global Recombinant DNA Vaccine Revenue Market Share by Type in 2021
Figure 3. Recombinant Protein Vaccine
Figure 4. Gene-Based Vaccine
Figure 5. Global Recombinant DNA Vaccine Revenue Market Share by Application in 2021
Figure 6. Human
Figure 7. Animal
Figure 8. Global Recombinant DNA Vaccine Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Recombinant DNA Vaccine Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Recombinant DNA Vaccine Sales (2017-2028) & (K Units)
Figure 11. Global Recombinant DNA Vaccine Price (2017-2028) & (US$/Unit)
Figure 12. Global Recombinant DNA Vaccine Production Capacity (2017-2028) & (K Units)
Figure 13. Global Recombinant DNA Vaccine Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Recombinant DNA Vaccine Market Drivers
Figure 15. Recombinant DNA Vaccine Market Restraints
Figure 16. Recombinant DNA Vaccine Market Trends
Figure 17. Global Recombinant DNA Vaccine Sales Market Share by Manufacturer in 2021
Figure 18. Global Recombinant DNA Vaccine Revenue Market Share by Manufacturer in 2021
Figure 19. Recombinant DNA Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Recombinant DNA Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Recombinant DNA Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Recombinant DNA Vaccine Sales Market Share by Region (2017-2028)
Figure 23. Global Recombinant DNA Vaccine Revenue Market Share by Region (2017-2028)
Figure 24. North America Recombinant DNA Vaccine Revenue (2017-2028) & (USD Million)
Figure 25. Europe Recombinant DNA Vaccine Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Recombinant DNA Vaccine Revenue (2017-2028) & (USD Million)
Figure 27. South America Recombinant DNA Vaccine Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Recombinant DNA Vaccine Revenue (2017-2028) & (USD Million)
Figure 29. Global Recombinant DNA Vaccine Sales Market Share by Type (2017-2028)
Figure 30. Global Recombinant DNA Vaccine Revenue Market Share by Type (2017-2028)
Figure 31. Global Recombinant DNA Vaccine Price by Type (2017-2028) & (US$/Unit)
Figure 32. Global Recombinant DNA Vaccine Sales Market Share by Application (2017-2028)
Figure 33. Global Recombinant DNA Vaccine Revenue Market Share by Application (2017-2028)
Figure 34. Global Recombinant DNA Vaccine Price by Application (2017-2028) & (US$/Unit)
Figure 35. North America Recombinant DNA Vaccine Sales Market Share by Type (2017-2028)
Figure 36. North America Recombinant DNA Vaccine Sales Market Share by Application (2017-2028)
Figure 37. North America Recombinant DNA Vaccine Sales Market Share by Country (2017-2028)
Figure 38. North America Recombinant DNA Vaccine Revenue Market Share by Country (2017-2028)
Figure 39. United States Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Recombinant DNA Vaccine Sales Market Share by Type (2017-2028)
Figure 43. Europe Recombinant DNA Vaccine Sales Market Share by Application (2017-2028)
Figure 44. Europe Recombinant DNA Vaccine Sales Market Share by Country (2017-2028)
Figure 45. Europe Recombinant DNA Vaccine Revenue Market Share by Country (2017-2028)
Figure 46. Germany Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Recombinant DNA Vaccine Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Recombinant DNA Vaccine Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Recombinant DNA Vaccine Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Recombinant DNA Vaccine Revenue Market Share by Region (2017-2028)
Figure 55. China Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Recombinant DNA Vaccine Sales Market Share by Type (2017-2028)
Figure 62. South America Recombinant DNA Vaccine Sales Market Share by Application (2017-2028)
Figure 63. South America Recombinant DNA Vaccine Sales Market Share by Country (2017-2028)
Figure 64. South America Recombinant DNA Vaccine Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Recombinant DNA Vaccine Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Recombinant DNA Vaccine Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Recombinant DNA Vaccine Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Recombinant DNA Vaccine Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Recombinant DNA Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Recombinant DNA Vaccine in 2021
Figure 76. Manufacturing Process Analysis of Recombinant DNA Vaccine
Figure 77. Recombinant DNA Vaccine Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 組換えヒトパピローマウイルス9価ワクチンのグローバル市場展望 2023年-2029年：女性、男性
  • 世界のアンチトロンビン（組換え）市場2022年：市場規模予測（～2028年）
  • 世界のフォン・ヴィレブランド因子（組換え）市場2022年：市場規模予測（～2028年）
  • 組換えカスケード試薬（rCR）＆組換えファクターCのグローバル市場展望 2023年-2029年：リコンビナントファクターC、リコンビナントカスケード試薬（rCR）
  • 卵不使用インフルエンザワクチンのグローバル市場展望 2023年-2029年：細胞培養インフルエンザワクチン、組換えインフルエンザワクチン
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19597 )"世界の組換えDNAワクチン市場2022年：市場規模予測（～2028年）" (英文：Global Recombinant DNA Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。